Method for detecting content of 3-quinuclidinol in penehyclidine hydrochloride injection

Through high performance liquid chromatography and gradient elution technology, combined with CAD detector, the sensitivity and accuracy of 3-quininol detection in verified hydrochloride injection was solved, achieving low detection limit and high repeatability. Meet safe medication needs.

CN118961923AInactive Publication Date: 2024-11-15YIGE PHARMA HUNAN PROV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411045243.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art cannot effectively and accurately detect the content of 3-quininol in verified hydrochloride injection, with low sensitivity, high detection limit, and complex detection methods, making it difficult to meet the needs of safe medication.

Method used

Using high-performance liquid chromatography, octadecylsilane bonded silica gel chromatography column, gradient elution method, combined with CAD detector, the content of 3-quinineol is calculated by the external standard method based on peak area, improving detection sensitivity and accuracy Spend.

Benefits of technology

It significantly improves the detection sensitivity of 3-quininol, and reduces the detection limit to 0.121μg/ml, meeting the quantitative detection requirements in verified verified hydrochloride injection, simple operation, low cost, accurate results, system applicability and speciality Good, repeatability and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118961923A_ABST
    Figure CN118961923A_ABST
Patent Text Reader

Abstract

The invention discloses a method for detecting the content of 3-quinuclidinol in penehyclidine hydrochloride injection. The method comprises the following steps: S1, preparing a reference solution and a test solution; s2, carrying out detection in a gradient elution mode by using a high performance liquid chromatography and a CAD (Computer Aided Design) detector; and S3, calculating the content of 3-quinuclidinol in the test solution by peak area according to an external standard method. According to the present invention, the detection of the impurity 3-quinuclidinol in the penehyclidine hydrochloride injection is achieved through the high performance liquid chromatography, and the detection method has advantages of simple and efficient operation, good reproducibility, low detection limit, high sensitivity, good linear relationship, high accuracy, good repeatability and good stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of drug analysis, in particular to a method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection. Background Art

[0002] Penehyclidine hydrochloride is a new type of anticholinergic drug, which was developed by the Chinese Academy of Military Medical Sciences and awarded the Class I new chemical drug by the State Food and Drug Administration in 1999. The existing dosage form of its raw material is injection, namely penehyclidine hydrochloride injection, which has a selective cholinergic receptor antagonist effect and is mainly used for pre-anesthetic administration to inhibit the secretion of salivary glands and airway glands, emergency treatment of organophosphorus poisoning (pesticides) poisoning, and maintenance of atropine in the late stage of poisoning or after aging of cholinesterase (ChE).

[0003] 3-Quinuclide is an intermediate product in the preparation of penehyclidine hydrochloride. During the storage of penehyclidine hydrochloride injection, its degradation products also include 3-quinuclide. In order to ensure the safety and effectiveness of the drug, 3-quinuclide needs to be studied and controlled. The structural formula of 3-quinuclide is as follows:

[0004]

[0005] According to its structural properties, it is poorly retained in a commonly used reversed-phase high-performance liquid chromatography column, and 3-quinuclol itself has no ultraviolet absorption. In the national drug standard (WS1-(X-026)-2004Z) of penehyclidine hydrochloride, the detection method of 3-quinuclol is thin layer chromatography, and this method has poor sensitivity and cannot accurately and quantitatively detect the content of 3-quinuclol. Most of the other prior arts are about the 3-quinuclol detection method in penehyclidine hydrochloride bulk drug, and the high performance liquid chromatography differential method and ultraviolet method are used for detection, and the detection limits are 4.4 μg / ml and 5.2 μg / ml respectively, with high detection limits, poor sensitivity, and high sample concentration required. Since the sample concentration in penehyclidine hydrochloride injection is 1 mg / ml, according to its limit 0.25%, the concentration of the reference solution is only 2.5 μg / ml. Therefore, the sensitivity of the above method is far from meeting the requirements and cannot meet the detection requirements of 3-quinuclol in penehyclidine hydrochloride injection. In addition, there is a prior art method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection by gas phase method, but the processing steps of the test solution and the reference solution are cumbersome and complicated, which easily causes the loss of 3-quinuclol, and the repeatability is also poor, and it is easy to remain, affecting the accuracy of the result. It can be seen that there is no detection method in the prior art that is simple and efficient in operation, highly sensitive, highly accurate, and reproducible, and can quantitatively detect the content of 3-quinuclol in penehyclidine hydrochloride injection. Summary of the invention

[0006] The invention provides a method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection, so as to solve the technical problem that the detection of the content of 3-quinuclol in penehyclidine hydrochloride injection in the prior art cannot have simple and efficient operation, high sensitivity, high accuracy and good reproducibility.

[0007] According to one aspect of the present invention, there is provided a method for detecting the content of 3-quinuclidine in penehyclidine hydrochloride injection, comprising the following steps:

[0008] 3-Quinuclide with a concentration of 1.25 μg / ml to 3.75 μg / ml is used as the reference solution; penehyclidine hydrochloride injection with a concentration of 0.5 mg / ml to 1.0 mg / ml is used as the test solution;

[0009] The reference solution and the test solution were tested by high performance liquid chromatography and the chromatograms were recorded. The test conditions included:

[0010] Chromatographic column: octadecylsilane bonded silica gel chromatographic column;

[0011] Mobile phase A: 0.1% to 0.25% trifluoroacetic acid aqueous solution;

[0012] Mobile phase B: acetonitrile;

[0013] Elution method: gradient elution;

[0014] Detector: CAD detector, data acquisition frequency 2Hz; filtering 3.6s; atomization chamber temperature: 50℃~60℃,

[0015] The content of 3-quinuclol in the test solution was calculated by the peak area according to the external standard method.

[0016] Furthermore, the solvent of the reference solution and the test solution is water.

[0017] Furthermore, the initial volume ratio of the mobile phase A to the mobile phase B is 97:3 to 94:6.

[0018] Furthermore, the volume percentage concentration of the trifluoroacetic acid aqueous solution is 0.1% to 0.25%.

[0019] Furthermore, before the reference solution and the test solution are tested by high performance liquid chromatography, the method includes measuring equal volumes of the reference solution and the test solution and injecting them into a liquid chromatograph.

[0020] Furthermore, the injection volumes of the reference solution and the test solution are both 20 μl to 40 μl.

[0021] Furthermore, the injection flow rates of the reference solution and the test solution are both 0.9-1.1 ml / min.

[0022] Furthermore, the temperature of the chromatographic column is 20-30°C.

[0023] Furthermore, the gradient elution includes an elution time of 0 to 20 minutes, in which the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B first decreases and then increases.

[0024] Further, the gradient elution comprises:

[0025] At 0 to 5 minutes after the start of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 94% to 97%;

[0026] During the 5.1-14 minutes of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 30%;

[0027] During the 14.1-20 minutes of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 94%-97%.

[0028] The present invention has the following beneficial effects:

[0029] (1) Compared with other methods, the method for detecting the content of 3-quinuclidine in penehyclidine hydrochloride injection of the present invention is simple to prepare, convenient to operate, and has lower cost. In addition, the test solution is directly injected, which is not affected by the preparation process and the result is more accurate.

[0030] (2) In the method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection of the present invention, the concentration of the reference solution is 1.25 μg / ml to 3.75 μg / ml, and the concentration of the test solution is 0.5 mg / ml to 1.0 mg / ml. Compared with other methods, the concentration is small, easy to clean, and no residue will remain.

[0031] (3) The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection of the present invention greatly improves the detection sensitivity of 3-quinuclol. The quantitative limit of 3-quinuclol in the detection method provided by the embodiment of the present invention is 0.243 μg / ml, which is less than 30% (0.25%) of the limit; the detection limit is 0.121 μg / ml, which is significantly lower than the detection limit of 4.4 μg / ml of the liquid phase differential method, the detection limit of 5.2 μg / ml of the liquid phase ultraviolet method, and the detection limit of 0.75 μg / ml of the gas phase method; the detection limit of this method is significantly lower than that of other methods, and the sensitivity is greatly improved, which can meet the quantitative detection of 3-quinuclol in penehyclidine hydrochloride injection.

[0032] (4) The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to the embodiment of the present invention provides a detection method with good system applicability: the theoretical plate number of 3-quinuclol in the reference solution is 11499 (greater than 3000), the asymmetry is 1.00 (less than 1.2), the reference solution is injected 5 times continuously, the retention time RSD of 3-quinuclol is 0.10%, the peak area RSD is 1.54%, and the RSD of the retention time and the peak area are both less than 2.0%, which meets the requirements, indicating that the system applicability of this method is good.

[0033] (5) The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to the embodiment of the present invention provides a detection method with good specificity: there is no interference from the blank solution; other impurities in the test solution have no interference with it, indicating that the method has good specificity.

[0034] (6) The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to the embodiment of the present invention has a good linear relationship: 3-quinuclol is in the range of 0.243 μg / ml to 4.857 μg / ml, the linear equation is y=0.0882x+0.0093, the linear correlation coefficient r=0.9996>0.999, and the Y-axis intercept accounts for 4.06% of the 100% response value, indicating that 3-quinuclol has a good linear relationship in the range of 0.243 μg / ml to 4.857 μg / ml;

[0035] (7) The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to the embodiment of the present invention has good repeatability: in the 6 spiked test solutions, the content determination results of 3-quinuclol were all 0.251%-0.260%, and the RSD value was 1.5% less than 3.0%, indicating that the method has good repeatability.

[0036] (8) The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to the embodiment of the present invention has good accuracy: the detected amount of 3-quinuclol in the test solution is only 0.090%, and 3-quinuclol in the concentration range of 1.2527 μg / ml to 3.7582 μg / ml is added to the test solution. The recovery rate is 94.27% to 104.96%, the average recovery rate is 98.9%, and the recovery rate is within the range of 90% to 108%. The RSD of the recovery rate is 3.9%, which is less than 6.0%, indicating that the method has good accuracy in detecting 3-quinuclol;

[0037] (9) The reference solution and the spiked test solution prepared by the method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to the embodiment of the present invention have good stability at room temperature: the reference solution is placed at room temperature for 41 hours, and the peak area of ​​3-quinuclol changes by 4.4% compared with that at 0 hours, which is less than 5.0%, indicating that the reference solution is stable after being placed at room temperature for 41 hours. The spiked test solution is placed at room temperature for 41 hours, and the change in the content of 3-quinuclol is 5.7%, which is less than 20%, indicating that the spiked test solution is stable after being placed at room temperature for 41 hours.

[0038] In addition to the above-described objects, features and advantages, the present invention has other objects, features and advantages. The present invention will be further described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] The drawings constituting a part of this application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0040] Figure 1 is a liquid chromatogram of a blank solution in a preferred embodiment of the present invention;

[0041] Figure 2 is a liquid chromatogram of a 3-quinuclol reference substance solution in a preferred embodiment of the present invention;

[0042] Figure 3 is a liquid chromatogram of the test solution in a preferred embodiment of the present invention;

[0043] Figure 4 is a liquid chromatogram of a spiked test solution in a preferred embodiment of the present invention;

[0044] Figure 5 is a quantitative limit liquid chromatogram of 3-quinuclidine in a preferred embodiment of the present invention;

[0045] Figure 6 is a liquid phase chromatogram with a detection limit of 3-quinuclidine in a preferred embodiment of the present invention;

[0046] Figure 7 It is a linear curve diagram of 3-quinuclidine in a preferred embodiment of the present invention. DETAILED DESCRIPTION

[0047] In order to make the invention purpose, technical scheme and beneficial technical effect of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. It should be understood that the embodiments described in this specification are only for explaining the present invention, not for limiting the present invention.

[0048] For simplicity, only some numerical ranges are explicitly disclosed herein. However, any lower limit can be combined with any upper limit to form an unambiguous range; and any lower limit can be combined with other lower limits to form an unambiguous range, and any upper limit can be combined with any other upper limit to form an unambiguous range. In addition, although not explicitly stated, each point or single value between the range endpoints is included in the range. Thus, each point or single value can be combined with any other point or single value as its own lower limit or upper limit or with other lower limits or upper limits to form an unambiguous range.

[0049] In the description of this article, it should be noted that, unless otherwise specified, “above” and “below” are inclusive of the number, and the “multiple” in “one or more” means two or more, and the “multiple” in “one or more” means two or more.

[0050] The embodiment of the present invention provides a method for detecting the content of 3-quinuclidine in penehyclidine hydrochloride injection, comprising the following steps:

[0051] 3-Quinuclide with a concentration of 1.25 μg / ml to 3.75 μg / ml is used as the reference solution; penehyclidine hydrochloride injection with a concentration of 0.5 mg / ml to 1.0 mg / ml is used as the test solution;

[0052] The reference solution and the test solution were tested by high performance liquid chromatography and the chromatograms were recorded. The test conditions included:

[0053] Chromatographic column: octadecylsilane bonded silica gel chromatographic column;

[0054] Mobile phase A: trifluoroacetic acid aqueous solution;

[0055] Mobile phase B: acetonitrile;

[0056] Elution method: gradient elution;

[0057] Detector: CAD detector, data acquisition frequency 2Hz; filtering 3.6s; atomization chamber temperature: 50℃~60℃;

[0058] The content of 3-quinuclol in the test solution was calculated by the peak area according to the external standard method.

[0059] In the embodiment of the present application, a CAD detector is selected, and the parameters of the CAD detector are data acquisition frequency 2 Hz, filtering 3.6 s, and atomization chamber temperature: 50°C to 60°C.

[0060] According to the embodiments of the present application, since 3-quinuclidine has no ultraviolet absorption, the above detector and parameters can ensure the response and peak shape of the 3-quinine peak to meet the sensitivity requirements. The CAD detector greatly improves the sensitivity of 3-quinuclidine, and solves the problem that the sensitivity of 3-quinuclidine in penehyclidine hydrochloride injection cannot meet the requirements by other methods.

[0061] In an embodiment of the present application, the reference solution described in S1 is prepared with water, and its concentration is 1.25μg / ml to 3.75μg / ml. For example, the concentration of the reference solution is 1.25μg / ml, 1.30μg / ml, 1.40μg / ml, 1.50μg / ml, 2.00μg / ml, 2.20μg / ml, 2.50μg / ml, 3.00μg / ml, 3.25μg / ml, 3.50μg / ml or 3.75μg / ml, etc. The concentration of the reference solution can also be any combination range of the above-mentioned numerical values.

[0062] In an embodiment of the present application, the test solution is directly injected with penehyclidine hydrochloride injection, and its concentration is 0.5 mg / ml to 1.0 mg / ml. For example, the concentration of the test solution is 0.5 mg / ml, 0.6 mg / ml, 0.7 mg / ml, 0.8 mg / ml, 0.9 mg / ml or 1.0 mg / ml, etc. The concentration of the test solution can also be any combination range of the above values.

[0063] According to the embodiments of the present application, selecting the above-mentioned reference solution concentration and test solution concentration can ensure the sensitivity of the method and control the detection cost.

[0064] In the embodiments of the present application, the test solution is penehyclidine hydrochloride injection, which can be directly injected (the penehyclidine hydrochloride injection is in a solution state, and when the concentration of its main component is 0.5 mg / ml to 1.0 mg / ml, it can be directly injected). Compared with other methods, this method is simple to prepare and easy to operate.

[0065] In the examples of the present application, the solvent of the reference solution and the test solution is water. In the present invention, the reference solution is directly prepared with water, which will not cause harm to the environment and personnel, and has lower cost.

[0066] In an embodiment of the present application, the initial volume ratio of the mobile phase A to the mobile phase B is 97:3 to 94:6.

[0067] According to the embodiments of the present application, since 3-quinuclol has poor retention in a reverse phase chromatography column, the above-mentioned initial ratio of the mobile phase is selected to increase the retention of 3-quinuclol and ensure that the separation of the 3-quinuclol peak and the adjacent peaks meets the requirements.

[0068] In the embodiments of the present application, the volume percentage concentration of the trifluoroacetic acid aqueous solution is 0.1% to 0.25%.

[0069] According to the embodiments of the present application, the volume percentage concentration of the trifluoroacetic acid aqueous solution is selected to ensure a smaller background current and reduce its effect on sensitivity.

[0070] In an embodiment of the present application, the method of detecting the reference solution and the test solution by high performance liquid chromatography includes: measuring equal volumes of the reference solution and the test solution and injecting them into a liquid chromatograph.

[0071] In the examples of the present application, the injection volumes of the reference solution and the test solution are both 20 μl to 40 μl.

[0072] In the examples of the present application, the injection flow rates of the reference solution and the test solution are both 0.9-1.1 ml / min.

[0073] According to the embodiments of the present application, the above flow rate is selected to ensure the rationality of the elution position of 3-quinuclidine.

[0074] In an embodiment of the present application, the temperature of the chromatographic column is 20-30°C.

[0075] According to the embodiments of the present application, the temperature of the above-mentioned chromatographic column is within the room temperature range, which is relatively easy to reach by the instrument, and the peak position of 3-quinuclidine is reasonable at the temperature of this chromatographic column.

[0076] In the embodiments of the present application, the gradient elution includes an elution time of 0 to 20 minutes, in which the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B first decreases and then increases.

[0077] In an embodiment of the present application, the gradient elution comprises:

[0078] At 0 to 5 minutes after the start of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 94% to 97%;

[0079] During the 5.1-14 minutes of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 30%;

[0080] During the 14.1-20 minutes of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 94%-97%.

[0081] According to the embodiments of the present application, the selection of the above-mentioned gradient elution can ensure that the relatively strong penehyclidine hydrochloride and other impurities can be eluted and will not remain in the next injection and interfere with the detection; and 3-quinuclidine can be separated from other impurities.

[0082] The following examples more specifically describe the disclosure of the present application, which are intended for illustrative purposes only, as it will be apparent to those skilled in the art that various modifications and variations may be made within the scope of the disclosure of the present application. Unless otherwise stated, all parts, percentages, and ratios reported in the following examples are by weight, and all reagents used in the examples are commercially available or synthesized according to conventional methods and can be used directly without further processing, and the instruments used in the examples are commercially available.

[0083] The present embodiment provides a method for determining the content of impurity 3-quinuclidine in penehyclidine hydrochloride injection, comprising the following steps:

[0084] S1. Prepare solution:

[0085] Solvent: water;

[0086] Preparation of 3-quinuclol mother solution: Weigh 20.30 mg of 3-quinuclol reference substance, place it in a 50 ml volumetric flask, add solvent to dissolve and dilute to the scale, shake well, and obtain.

[0087] Preparation of reference solution: Accurately measure 3.0 ml of 3-quinuclol mother solution, place it in a 50 ml volumetric flask, dilute to the mark with solvent, shake well, accurately measure 5.0 ml, place it in a 50 ml volumetric flask, dilute to the mark with solvent, shake well, and obtain.

[0088] Test solution: Take penehyclidine hydrochloride injection and inject directly.

[0089] S2. Liquid chromatography detection:

[0090] Accurately measure 20 μl of the reference solution and the test solution, respectively, and inject them into the liquid chromatograph to record the chromatogram. If there is a peak in the chromatogram of the test solution that is consistent with the peak position of the impurity peak in the reference solution, calculate the peak area according to the external standard method. The calculation formula is as follows:

[0091] 3-Quinuclide content (%) = A 供 ×C 对 / A 对 / C 供 / 1000×100%

[0092] Wherein, impurity content (%): mass percentage of 3-quinuclidine; A 供试 : 3-quinuclidine peak area in the test solution, unit is mV*min; A对照 : 3-quinuclidine peak area in the reference solution, unit is mV*min; C 对 : The concentration of the reference solution, in μg / ml; C 供 : Concentration of the test solution, in mg / ml.

[0093] The above liquid chromatography conditions are as follows:

[0094] Chromatographic column: Octadecylsilane bonded silica gel as filler (SHIMADZU Shim-pack GIST C18-AQ, 4.6mm×250mm, 5μm)

[0095] Detector: CAD detector (parameters: data acquisition frequency 2Hz, filtering 3.6s, atomization chamber temperature: 50℃~60℃)

[0096] Flow rate: 0.9~1.1ml / min;

[0097] Column temperature: 20-30°C;

[0098] Injection volume: 20-40 μl;

[0099] Mobile phase A: 0.1% to 0.25% trifluoroacetic acid solution;

[0100] Mobile phase B: acetonitrile.

[0101] The gradient elution method is shown in Table 1 below:

[0102] Table 1 Gradient elution method

[0103] Time (min) Mobile phase A (%) Mobile phase B (%) 0 95 5 5.0 95 5 5.1 30 70 14 30 70 14.1 95 5 20 95 5

[0104] Analysis of the system applicability and specificity results of the detection method in the embodiment of the present invention:

[0105] The blank solution, reference solution, test solution, and spiked test solution in the present invention are shown in the following test patterns: Figure 1 to Figure 4 , the results are shown in Tables 2 and 3.

[0106] Table 2 Specificity test results

[0107]

[0108] From Table 2, we can see that the theoretical plate number of 3-quinuclidine in the reference solution is 11499 (greater than 3000), and the asymmetry is 1.00 (less than 1.2); the blank solution has no interference; other impurities in the test solution have no interference, indicating that this method has good specificity.

[0109] Table 3 System suitability-injection precision results

[0110]

[0111]

[0112] From Table 3, we can see that the reference solution was injected 5 times continuously, the retention time RSD of 3-quinuclol was 0.10%, the peak area RSD was 1.54%, and the RSD values ​​were all less than 2.0%, which met the requirements, indicating that the system applicability of this method is good.

[0113] The results of the quantitative limit and detection limit of 3-quinuclol in the examples of the present invention are shown in Table 4 and Figure 4. Figure 5-6 .

[0114] Table 4 Results of the quantitative limit and detection limit of quinuclidine in Example 3 of the present invention

[0115]

[0116] As shown in Table 4, the quantification limit of 3-quinuclidine is 0.243 μg / ml, equivalent to 0.024% of the test solution concentration, the signal-to-noise ratio is 21.3, greater than 10, the detection limit is 0.121 μg / ml, equivalent to 0.012% of the test solution concentration, and the signal-to-noise ratio in the chromatogram of the detection limit solution is 6.3, greater than 3. This shows that the method has good sensitivity to 3-quinuclidine.

[0117] The linearity and range of the embodiments of the present invention are:

[0118] Linear solution: Take an appropriate amount of 3-quinuclidine reference substance, prepare a series of solutions with different concentrations, and measure according to the detection method of the embodiment. The measurement results are shown in Table 5.

[0119] Table 5 Peak area test results and standard curve of 3-quinuclidine reference substance at different concentrations

[0120]

[0121] As can be seen from Table 5, within the range of 0.243 μg / ml to 4.857 μg / ml, the linear equation of 3-quinuclidine is y=0.0882x+0.0093, the regression coefficient R of the regression curve is 0.9996, not less than 0.990, and the Y-axis intercept accounts for 4.06% of the 100% response value, indicating that 3-quinuclidine has a good linear relationship within this concentration range. Figure 7 This is the linear curve graph of 3-quinuclidine.

[0122] Repeatability of the embodiments of the present invention:

[0123] Since the detected amount of 3-quinuclidine in penehyclidine hydrochloride injection is small, the repeatability test was carried out with the spiked test solution. The results are shown in Table 6.

[0124] Table 6 Example 3 of the present invention - Quinuclidine repeatability test results

[0125] name Peak area content% Spiked sample-1 0.2567 0.253 Spiked sample-2 0.2548 0.252 Spiked sample-3 0.2589 0.256 Spiked sample-4 0.2612 0.258 Spiked sample-5 0.2538 0.251 Spiked sample-6 0.2630 0.260 Mean(%) — 0.255 RSD value — 1.5%

[0126] As can be seen from Table 6, the RSD value of the determination results of 3-quinuclidine content in 6 spiked test solutions is 1.5%, which is less than 3.0%, so the method has good repeatability.

[0127] Accuracy test of the detection method in the embodiment of the present invention:

[0128] Prepare the following solution:

[0129] Reference substance mother solution: Take 3-quinuclol①25.10mg,②25.13mg, respectively, and place them in 20ml volumetric flasks, add water to dissolve and dilute to the scale, shake well, and obtain.

[0130] Reference substance stock solution: Accurately measure 5.0 ml of each reference substance mother solution and place them in 100 ml volumetric flasks, dilute to the scale with water, shake well, and obtain.

[0131] Reference substance solution: Accurately measure 1.0 ml of each reference substance stock solution, place it in a 25 ml volumetric flask, dilute to the mark with water, shake well (2.5 μg / ml), and prepare 2 parallel portions.

[0132] Test solution: Take penehyclidine hydrochloride injection and inject directly.

[0133] 50% recovery solution: Accurately measure 0.5 ml of reference stock solution ①, place in a 25 ml volumetric flask, and dilute to the mark with penehyclidine hydrochloride injection. Prepare 3 portions in parallel.

[0134] 100% recovery solution: Accurately measure 1.0 ml of reference stock solution ①, place in a 25 ml volumetric flask, and dilute to the mark with penehyclidine hydrochloride injection. Prepare 3 portions in parallel.

[0135] 150% recovery solution: Accurately measure 1.5 ml of reference stock solution ①, place in a 25 ml volumetric flask, and dilute to the mark with penehyclidine hydrochloride injection. Prepare 3 portions in parallel.

[0136] Accurately measure 20 μl of each of the above solutions and measure according to the chromatographic conditions in this example. The 3-quinuclol content in the test solution is calculated to be 0.090%. The background value is calculated based on this content, and then the recovery rate is calculated. The results are shown in Table 7.

[0137] Table 7 Recovery test results of 3-quinuclidine in the detection method of the embodiment of the present invention

[0138]

[0139]

[0140] As shown in Table 7, when 3-quinuclidine in the concentration range of 1.2527 μg / ml to 3.7582 μg / ml was added to the test solution, the recovery rate was between 94.27% and 104.96%, the average recovery rate was 98.9%, and the recovery rate was within the range of 90% to 108%. The RSD of the recovery rate was 3.9%, which was less than 6.0%, indicating that the method had good accuracy in detecting 3-quinuclidine.

[0141] Solution stability test of the detection method in the embodiment of the present invention:

[0142] At room temperature, the 3-quinuclol reference solution and the spiked test solution were placed at room temperature for 41 hours, and the measurements were performed at 0 hours, 8 hours, 16 hours, 24 hours, and 41 hours, respectively. The results showed that when the reference solution was placed at room temperature for 41 hours, the change rate of the peak area of ​​3-quinuclol compared with that at 0 hour was 4.4%, which was less than 5.0%; when the spiked test solution was placed at room temperature for 41 hours, the change in the 3-quinuclol content was 5.7%, which was less than 10%, indicating that the reference solution and the spiked test solution were stable after being placed at room temperature for 41 hours.

[0143] The system applicability, specificity, detection line and quantification limit, linear range, accuracy and solution stability of the method for detecting the impurity 3-quinuclol in penehyclidine hydrochloride injection were verified. The experimental results showed that this method can be used to determine the impurity 3-quinuclol in penehyclidine hydrochloride injection.

[0144] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for detecting the content of 3-quinuclidine in penehyclidine hydrochloride injection, characterized in that: The steps include: 3-Quinuclide with a concentration of 1.25 μg / ml to 3.75 μg / ml is used as the reference solution; penehyclidine hydrochloride injection with a concentration of 0.5 mg / ml to 1.0 mg / ml is used as the test solution; The reference solution and the test solution were tested by high performance liquid chromatography and the chromatograms were recorded. The test conditions included: Chromatographic column: octadecylsilane bonded silica gel chromatographic column; Mobile phase A: trifluoroacetic acid aqueous solution; Mobile phase B: acetonitrile; Elution method: gradient elution; Detector: CAD detector, data acquisition frequency 2Hz; filtering 3.6s; atomization chamber temperature: 50℃~60℃; The content of 3-quinuclol in the test solution was calculated by the peak area according to the external standard method.

2. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 1, characterized in that: The solvent of the reference solution and the test solution is water.

3. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 1, characterized in that: The initial volume ratio of the mobile phase A to the mobile phase B is 97:3 to 94:

6.

4. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 1, characterized in that: The volume percentage concentration of the trifluoroacetic acid aqueous solution is 0.1% to 0.25%.

5. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 1, characterized in that: Before testing the reference solution and the test solution by high performance liquid chromatography, the process includes measuring equal volumes of the reference solution and the test solution and injecting them into the liquid chromatograph.

6. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 5, characterized in that: The injection volumes of the reference solution and the test solution are both 20 μl to 40 μl.

7. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 5, characterized in that: The injection flow rates of the reference solution and the test solution are both 0.9-1.1 ml / min.

8. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 1, characterized in that: The temperature of the chromatographic column is 20-30°C.

9. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 1, characterized in that: The gradient elution includes that within an elution time of 0 to 20 minutes, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B first decreases and then increases.

10. The method for detecting the content of 3-quinuclol in penehyclidine hydrochloride injection according to claim 1, characterized in that: The gradient elution comprises: At 0 to 5 minutes after the start of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 94% to 97%; During the 5.1-14 minutes of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 30%; During the 14.1-20 minutes of elution, the percentage of the mobile phase A in the total volume of the mobile phase A and the mobile phase B is 94%-97%.